GEIS is an internationally renowned non-profit organization focused on the research and development of drugs for sarcoma cancers.
Following completion of the Monopar-sponsored Phase 1b clinical trial, Monopar anticipates that GEIS will be conducting a multi-country, randomized, open-label Phase 2 clinical trial in a first line setting to evaluate camsirubicin head-to-head against doxorubicin in patients with advanced soft tissue sarcoma.
In June 2020, Monopar entered into a collaboration with NorthStar Medical Radioisotopes, LLC, to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection), coupling MNPR-101 to therapeutic radioisotopes supplied by NorthStar. This collaboration combines NorthStar’s expertise in the innovative production, supply, and distribution of important medical radioisotopes with Monopar's expertise in therapeutic drug development.
NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes.
In May 2021, Monopar entered into a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer.
CSI Singapore is one of only five Research Centres of Excellence established by the Government of Singapore with funding from the National Research Foundation and the Ministry of Education. Its mission is to better understand the causes of human cancer across Asia, and thereby improve its detection, treatment and prevention for the benefit of the patients. The CSI is internationally recognized for its innovative research on the biology of cancers prevalent in Asia, and for taking new methods for cancer treatment from the laboratory to the clinic.